GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ACME Laboratories Ltd (DHA:ACMELAB) » Definitions » Net-Net Working Capital

ACME Laboratories (DHA:ACMELAB) Net-Net Working Capital : BDT-101.30 (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is ACME Laboratories Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

ACME Laboratories's Net-Net Working Capital for the quarter that ended in Dec. 2024 was BDT-101.30.

The industry rank for ACME Laboratories's Net-Net Working Capital or its related term are showing as below:

DHA:ACMELAB's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.93
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

ACME Laboratories Net-Net Working Capital Historical Data

The historical data trend for ACME Laboratories's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACME Laboratories Net-Net Working Capital Chart

ACME Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only -67.24 -67.90 -67.96 -87.25 -96.32

ACME Laboratories Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -96.58 -96.32 -94.62 -101.30

Competitive Comparison of ACME Laboratories's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACME Laboratories's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where ACME Laboratories's Price-to-Net-Net-Working-Capital falls into.


;
;

ACME Laboratories Net-Net Working Capital Calculation

ACME Laboratories's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Jun. 2024 is calculated as

Net-Net Working Capital(A: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1808.335+0.75 * 3259.015+0.5 * 11871.484-30570.334
-0-0)/211.602
=-96.32

ACME Laboratories's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2024 is calculated as

Net-Net Working Capital(Q: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(2392.666+0.75 * 3398.133+0.5 * 12497.925-32624.954
-0-0)/211.602
=-101.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


ACME Laboratories  (DHA:ACMELAB) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


ACME Laboratories Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of ACME Laboratories's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


ACME Laboratories Business Description

Traded in Other Exchanges
N/A
Address
1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.

ACME Laboratories Headlines

No Headlines